4.8 Article

Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study

Journal

JOURNAL OF HEPATOLOGY
Volume 63, Issue 2, Pages 470-476

Publisher

ELSEVIER
DOI: 10.1016/j.jhep.2015.02.045

Keywords

Fatty liver; Abdominal aortic calcium; Coronary artery calcium; Cardiovascular disease

Funding

  1. National Institutes of Health [K23DK080145-01]
  2. Doris Duke Medical Foundation
  3. University of Michigan Internal Medicine Department, Division of Gastroenterology, and Biological Sciences Scholars Program
  4. National Institute of Neurological Disorders and Stroke [NS17950]
  5. National Institute of Aging [AG08122, AG033193]
  6. [T32DK062708]

Ask authors/readers for more resources

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and is associated with development of metabolic disease including atherosclerotic cardiovascular disease (CVD). Our aim is to examine the association of hepatic steatosis with prevalent clinical and subclinical CVD outcomes in a large community-based sample, the Framingham Heart Study. Methods: Hepatic steatosis was measured in 3529 participants using multidetector computed tomography scanning. Multivariable logistic regression was used to determine whether hepatic steatosis is associated with prevalent CVD adjusted for covariates. We also tested whether associations were independent of other metabolic diseases/traits. The primary clinical outcome was composite prevalent clinical CVD defined by prior non-fatal myocardial infarction, stroke, transient ischemic attack, heart failure, or peripheral arterial disease. Subclinical cardiovascular outcomes were coronary artery calcium (CAC) and abdominal artery calcium (AAC). Results: 3014 participants were included (50.5% women). There was a non-significant association of hepatic steatosis with clinical CVD (OR 1.14 [p = 0.07]). Hepatic steatosis was associated with both CAC and AAC (OR 1.20 [p < 0.001] and OR 1.16 [p < 0.001], respectively). Associations persisted for CAC even when controlling for other risk factors/metabolic diseases, but for AAC, the associations became non-significant after adjustment for visceral adipose tissue. The association between hepatic steatosis and AAC was stronger in men than in women (p sex interaction = 0.022). Conclusion: There was a significant association of hepatic steatosis with subclinical CVD outcomes independent of many metabolic diseases/traits with a trend towards association between hepatic steatosis and clinical CVD outcomes. The association with AAC was stronger in men than in women. (C) 2015 Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available